SML3154

Topiroxostat

≥98% (HPLC)

• Synonym(e): 4-[3-(4-Pyridinyl)-1H-1,2,4-triazol-5-yl]-2-pyridinecarbonitrile, 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, 5-(2-Cyano-4-pyridyl)-3-(4-pyridyl)-1,2,4-triazole, FYX 051, FYX-051
• Empirische Formel (Hill-System): C₁₃H₈N₆
• CAS-Nummer: 577778-58-6
• Molekulargewicht: 248.24
• MDL-Nummer: MFCD17167057
• UNSPSC-Code: 51111800
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear (warmed)
• Lagertemp.: 2-8°C
• SMILES String: N#CC1=NC=CC(C2=NNC(C3=CC=NC=C3)=N2)=C1
• InChI: 1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
• InChIKey: UBVZQGOVTLIHLH-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

Topiroxostat (FYX-051) is an orally active and potent inhibitor of xanthine oxidoreductase (XOR). It appears that inhibition of XOR by topiroxostat is due to the formation a covalent linkage to molybdenum via oxygen in the hydroxylation reaction intermediate. Also, topiroxostat displayed a potent, non-covalent inhibition of XOR. It is approved for the treatment of gout and hyperuricemia in Japan.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable